Global Hepatitis B and C Diagnostics Market Size, Status and Forecast 2019-2025

Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.
The increasing demand for molecular diagnostic of HBV (hepatitis B virus) and HCV (hepatitis C virus) infections is one of the primary drivers for the growth of this market. Molecular diagnosis simplifies sample preparation for high-volume testing and includes identification and profiling of causative agents of infection and the quantification of pathogens to monitor durability of therapy; thus, resulting in sales of around 60% of the overall molecular diagnosis market. Additionally, new companies are also focusing on the development of new products, which, in turn, is expected to change market dynamics for the diagnosis of HBV and HCV infections. For instance, Cepheid recently announced a quantitative test that offers on-demand molecular testing for confirmation of infection and monitoring of HCV and has obtained CE-IVD (in vitro diagnostics) status under the European Directive on in-vitro diagnostic medical devices, making it one of the leading platforms for molecular diagnosis.
Increasing incidence of HBV and HCV infections in the Americas will contribute to the growth of the diagnostic market. The Americas will dominate the market, accounting for half of the total market share by 2023. The recent increase in blood transfusion will result in the adoption of third-generation hepatitis C diagnostic tests like HCV enzyme immunoassay that contribute to the growth of the market in this region. Also, the implementation of biomarker-based POC (point-of-care) tests initiated by the government and non-profit organizations, is also expected to drive the market growth as the products are highly accessible and easy to use.
In 2018, the global Hepatitis B and C Diagnostics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Hepatitis B and C Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hepatitis B and C Diagnostics development in United States, Europe and China.

The key players covered in this study
Roche Diagnostics
Abbott
Siemens
Qiagen
Alere
bioMérieux
Cepheid
Chembio Diagnostics
DiaSorin
Enzo Life Sciences
Hologic
MedMira
OraSure Technologies
Quest Diagnostics
Quidel Corp
Randox Laboratories

Market segment by Type, the product can be split into
Hepatitis B
Hepatitis C

Market segment by Application, split into
Immunodiagnostics
Nucleic Acid Test (NAT)

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Hepatitis B and C Diagnostics status, future forecast, growth opportunity, key market and key players.
To present the Hepatitis B and C Diagnostics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Hepatitis B and C Diagnostics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.